Tags

Type your tag names separated by a space and hit enter

Recent advances in pharmacological treatment of irritable bowel syndrome.
World J Gastroenterol. 2014 Jul 21; 20(27):8867-85.WJ

Abstract

Irritable bowel syndrome (IBS) is a highly prevalent functional disorder that reduces patients' quality of life. It is a chronic disorder characterized by abdominal pain or discomfort associated with disordered defecation in the absence of identifiable structural or biochemical abnormalities. IBS imposes a significant economic burden to the healthcare system. Alteration in neurohumoral mechanisms and psychological factors, bacterial overgrowth, genetic factors, gut motility, visceral hypersensitivity, and immune system factors are currently believed to influence the pathogenesis of IBS. It is possible that there is an interaction of one or more of these etiologic factors leading to heterogeneous symptoms of IBS. IBS treatment is predicated upon the patient's most bothersome symptoms. Despite the wide range of medications and the high prevalence of the disease, to date no completely effective remedy is available. This article reviews the literature from January 2008 to July 2013 on the subject of IBS peripherally acting pharmacological treatment. Drugs are categorized according to their administration for IBS-C, IBS-D or abdominal pain predominant IBS.

Authors+Show Affiliations

Georgia Lazaraki, Grigoris Chatzimavroudis, Panagiotis Katsinelos, Department of Endoscopy and Motility Unit, G. Gennimatas General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54635 Thessaloniki, Greece.Georgia Lazaraki, Grigoris Chatzimavroudis, Panagiotis Katsinelos, Department of Endoscopy and Motility Unit, G. Gennimatas General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54635 Thessaloniki, Greece.Georgia Lazaraki, Grigoris Chatzimavroudis, Panagiotis Katsinelos, Department of Endoscopy and Motility Unit, G. Gennimatas General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54635 Thessaloniki, Greece.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25083060

Citation

Lazaraki, Georgia, et al. "Recent Advances in Pharmacological Treatment of Irritable Bowel Syndrome." World Journal of Gastroenterology, vol. 20, no. 27, 2014, pp. 8867-85.
Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(27):8867-85.
Lazaraki, G., Chatzimavroudis, G., & Katsinelos, P. (2014). Recent advances in pharmacological treatment of irritable bowel syndrome. World Journal of Gastroenterology, 20(27), 8867-85. https://doi.org/10.3748/wjg.v20.i27.8867
Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent Advances in Pharmacological Treatment of Irritable Bowel Syndrome. World J Gastroenterol. 2014 Jul 21;20(27):8867-85. PubMed PMID: 25083060.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent advances in pharmacological treatment of irritable bowel syndrome. AU - Lazaraki,Georgia, AU - Chatzimavroudis,Grigoris, AU - Katsinelos,Panagiotis, PY - 2013/10/01/received PY - 2014/03/13/revised PY - 2014/06/20/accepted PY - 2014/8/2/entrez PY - 2014/8/2/pubmed PY - 2015/4/18/medline KW - Constipation KW - Diarrhea KW - Irritable bowel syndrome KW - Irritable bowel syndrome constipation KW - Irritable bowel syndrome treatment KW - Irritable bowel syndrome-diarrhea KW - Irritable bowel syndrome-pain SP - 8867 EP - 85 JF - World journal of gastroenterology JO - World J Gastroenterol VL - 20 IS - 27 N2 - Irritable bowel syndrome (IBS) is a highly prevalent functional disorder that reduces patients' quality of life. It is a chronic disorder characterized by abdominal pain or discomfort associated with disordered defecation in the absence of identifiable structural or biochemical abnormalities. IBS imposes a significant economic burden to the healthcare system. Alteration in neurohumoral mechanisms and psychological factors, bacterial overgrowth, genetic factors, gut motility, visceral hypersensitivity, and immune system factors are currently believed to influence the pathogenesis of IBS. It is possible that there is an interaction of one or more of these etiologic factors leading to heterogeneous symptoms of IBS. IBS treatment is predicated upon the patient's most bothersome symptoms. Despite the wide range of medications and the high prevalence of the disease, to date no completely effective remedy is available. This article reviews the literature from January 2008 to July 2013 on the subject of IBS peripherally acting pharmacological treatment. Drugs are categorized according to their administration for IBS-C, IBS-D or abdominal pain predominant IBS. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/25083060/Recent_advances_in_pharmacological_treatment_of_irritable_bowel_syndrome_ L2 - https://www.wjgnet.com/1007-9327/full/v20/i27/8867.htm DB - PRIME DP - Unbound Medicine ER -